Covid 19 vaccine Pfizer is suggested to be more effective in neutralising Beta, Gamma variant. A recent study from the New York University stated.
Pfizer BNT162b2 Vaccinations Works More Efficiently
As per the latest reports, the study was led by the researchers from the New York University. It showed that the Pfizer BNT162b2 vaccination has worked well against the majority of the variants. But the vaccine neutralised the South African variant and the Brazil variant with a 3-fold decrease in titer.
Nathaniel “Ned” Landau, Professor in the Department of Microbiology at the NYU Grossman School of Medicine, in New York City said that their interpretation of the results is that the vaccine has powerful antibodies. And even if the loss is 3 fold of the titer, there are still a lot of antibodies left to neutralize the virus.
ALSO READ:Pfizer says vaccine highly effective against Indian covid strain, puts condition of indemnity
He said that they believe the findings demonstrate that the vaccines will remain protective against the variants that they tested.
The study, published in the journal mBio, also found that monoclonal antibody cocktail consisting of casirivamab and imdevimab might be less effective against SARS-CoV-2 variants in laboratory experiments.
REGN-COV2 Shows Casirivamab Had Lost Some of its Neutralising Activity
Lab experiments on Regeneron pharmaceuticals’ REGN-COV2 which is a 2 recombinant monoclonal antibody cocktail, showed that casirivamab had lost some of its neutralising activity against the South African and Brazilian variants and the cocktail was 9- to 15-fold decreased in titer, the research team said.
“One of the Regeneron antibodies is affected by the E484K mutation, and as a result the cocktail loses some of its neutralizing activity,” said Landau.
ALSO READ:‘Pfizer-BioNTech vax very effective against variants’
Landau further noted that the question with this kind of work is to understand how the laboratory findings would translate into the clinical effects. Further adding that they cannot guarantee that for sure. They will only be able to tell the results when the clinical data comes in.
The team created a panel of pseudotyped viruses using the spike proteins from six different variants of SARS-CoV-2: the B117 lineage variant identified in the UK, the B1351 lineage variant identified in South Africa, the B11248 lineage variant identified in Brazil, the COH.20G/677H lineage variant identified in Columbus Ohio, the 20 EUs variant identified in Spain and later found elsewhere in Europe, and the Mink cluster five spike proteins located in minks in Denmark.
